Drug Trial Radar · NCT05399030
A Phase I Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Study of ICP-332 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Aug 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Aug 14, 2021
Primary completion
Jan 30, 2022
Study completion Feb 18, 2022
Sponsor
- Lead sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, parallel group, single and multiple ascending dose phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ICP-332 in Healthy Subjects
Conditions
- Healthy Subjects
Interventions
ICP-332Drug
ICP-332 will be administered as tablet
PlaceboOther
Matching placebo will be administered as tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Treatment-Emergent Adverse Events (AEs).Time frame: Baseline up to 28 days after last dose.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jinan Central Hospital
Jinan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.